Lukin, Dana Jeremy

Publications

Sort by

Co-Author Network

selected publications

Shifting the Inflammatory Balance in Ulcerative Colitis Through Diet: A Mediterranean Diet Pattern is Associated with Improvements in Dysbiosis and Disease Activity. Journal of Crohn's & colitis. 2023 Editorial Article GET IT
PRO Tips: First-Rate Guidance for Second-Line Therapy After Tumor Necrosis Factor-Alpha Exposure in Patients with Crohn's Disease. Digestive diseases and sciences. 2023 Editorial Article GET IT
Times cited: 49
Increased Primary Bile Acids with Ileocolonic Resection Impact Ileal Inflammation and Gut Microbiota in Inflammatory Bowel Disease. Journal of Crohn's & colitis. 2023 Academic Article GET IT
The Impact of Confounders on Symptom-Endoscopic Discordances in Crohn's Disease. Crohn's & colitis 360. 2023 Academic Article GET IT
Long-Term Outcomes of the Excluded Rectum in Crohn's Disease: A Multicenter International Study. Inflammatory bowel diseases. 2023 Review GET IT
Serum Ustekinumab Concentrations Are Associated With Improved Outcomes With the Magnetic Resonance Index of Activity for Crohn's Disease. Inflammatory bowel diseases. 2022 Academic Article GET IT
Predicting inpatient mortality in patients with inflammatory bowel disease: A machine learning approach. Journal of gastroenterology and hepatology. 2022 Academic Article GET IT
COVID-19 is not associated with worse long-term inflammatory bowel disease outcomes: a multicenter case-control study. Therapeutic advances in gastroenterology. 2022 Academic Article GET IT
Article Topic: Positioning Ulcerative Colitis Therapies in 2022 and Beyond. Current gastroenterology reports. 2022 Review GET IT
The Real-World Effectiveness and Safety of Ustekinumab in the Treatment of Crohn's Disease: Results From the SUCCESS Consortium. The American journal of gastroenterology. 2022 Academic Article GET IT
Times cited: 6
Prevalence and factors associated with vitamin C deficiency in inflammatory bowel disease. World journal of gastroenterology. 2022 Academic Article GET IT
Times cited: 4
Recommendations on the Appropriate Management of Steroids and Discharge Planning During and After Hospital Admission for Moderate-Severe Ulcerative Colitis: Results of a RAND Appropriateness Panel. The American journal of gastroenterology. 2022 Review GET IT
Times cited: 2
A Quality Improvement Initiative Is Associated With Reduced Time to Administer Biologics and Small Molecules and Emergency Room Visits in Inflammatory Bowel Disease. Journal of clinical gastroenterology. 2022 Academic Article GET IT
Times cited: 3
Joint Disease Activity in Inflammatory Bowel Disease-associated Peripheral Spondyloarthritis Stratifies Therapeutic Response. Gastro hep advances. 2022 Academic Article GET IT
Impact of Inflammatory Bowel Disease Therapies on Durability of Humoral Response to SARS-CoV-2 Vaccination. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2021 Letter GET IT
Times cited: 9
A step towards informed positioning of advanced therapies for moderate-to-severe Crohn's disease. The lancet. Gastroenterology & hepatology. 2021 Comment GET IT
Immunogenicity of Tumor Necrosis Factor Antagonists and Effect of Dose Escalation on Anti-Drug Antibodies and Serum Drug Concentrations in Inflammatory Bowel Disease. Inflammatory bowel diseases. 2021 Academic Article GET IT
Times cited: 14
No Durable Impact of COVID-19 on Intestinal Disease Activity in Subjects With IBD. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2021 Academic Article GET IT
Times cited: 7
Ileal Pouch Anal Anastomosis for the Management of Ulcerative Colitis Is Associated With Significant Disability. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2021 Academic Article GET IT
Times cited: 6
Finding a Needle in the Haystack? Defining the Role of Random Biopsies in IBD Dysplasia Surveillance. Inflammatory bowel diseases. 2021 Comment GET IT
Dual Biologic or Small Molecule Therapy for Treatment of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2021 Review GET IT
Times cited: 44
Bacterial Swarmers Enriched During Intestinal Stress Ameliorate Damage. Gastroenterology. 2021 Academic Article GET IT
Times cited: 10
Deciphering structural bases of intestinal and hepatic selectivity in targeting pregnane X receptor with indole-based microbial mimics. Bioorganic chemistry. 2021 Academic Article GET IT
Times cited: 6
Comparative Safety and Effectiveness of Vedolizumab to Tumor Necrosis Factor Antagonist Therapy for Ulcerative Colitis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2020 Academic Article GET IT
Times cited: 18
Patient-Preferences Favoring Treatment Discontinuation Are Reduced With Vedolizumab and Ustekinumab Compared With TNF Antagonists in Inflammatory Bowel Disease. Crohn's & colitis 360. 2020 Academic Article GET IT
Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease. Alimentary pharmacology & therapeutics. 2020 Academic Article GET IT
Times cited: 35
Comorbid Diabetes in Inflammatory Bowel Disease Predicts Adverse Disease-Related Outcomes and Infectious Complications. Digestive diseases and sciences. 2020 Academic Article GET IT
Times cited: 5
Scattered Skin Eruptions in a Patient With Inflammatory Bowel Disease. 2020 GET IT
Baseline Disease Activity and Steroid Therapy Stratify Risk of COVID-19 in Patients With Inflammatory Bowel Disease. Gastroenterology. 2020 Academic Article GET IT
Times cited: 84
Predictors of Perianal Fistula Relapse in Crohn's Disease. Inflammatory bowel diseases. 2020 Editorial Article GET IT
Times cited: 6
Defining the phenotype, pathogenesis and treatment of Crohn's disease associated spondyloarthritis. Journal of gastroenterology. 2020 Review GET IT
Times cited: 4
Development and Validation of Clinical Scoring Tool to Predict Outcomes of Treatment With Vedolizumab in Patients With Ulcerative Colitis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2020 Academic Article GET IT
Times cited: 39
Incident heart failure is a predictor of adverse outcomes in inflammatory bowel disease. European journal of gastroenterology & hepatology. 2020 Academic Article GET IT
Times cited: 2
Vaccination in the Elderly and IBD. Current treatment options in gastroenterology. 2019 Review GET IT
Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes. Inflammatory bowel diseases. 2019 Academic Article GET IT
Times cited: 7
Escalation of Immunosuppressive Therapy for Inflammatory Bowel Disease Is Not Associated With Adverse Outcomes After Infection With Clostridium difficile. Inflammatory bowel diseases. 2019 Academic Article GET IT
Times cited: 14
Disability in inflammatory bowel disease patients is associated with race, ethnicity and socio-economic factors. Alimentary pharmacology & therapeutics. 2019 Academic Article GET IT
Times cited: 14
Shorter Disease Duration Is Associated With Higher Rates of Response to Vedolizumab in Patients With Crohn's Disease But Not Ulcerative Colitis. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2019 Academic Article GET IT
Times cited: 32
Correction: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium. The American journal of gastroenterology. 2018 Article GET IT
Times cited: 2
Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease. Inflammatory bowel diseases. 2018 Academic Article GET IT
Times cited: 44
Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2018 Academic Article GET IT
Times cited: 48
Intestinal Spirochetosis Resembles Inflammatory Bowel Disease in a Patient With HIV Infection. 2018 GET IT
Times cited: 1
Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium. The American journal of gastroenterology. 2018 Academic Article GET IT
Times cited: 103
Helicobacter pylori is associated with increased risk of serrated colonic polyps: Analysis of serrated polyp risk factors. Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology. 2018 Academic Article GET IT
Times cited: 10
Development and Validation of a Scoring System to Predict Outcomes of Vedolizumab Treatment in Patients With Crohn's Disease. Gastroenterology. 2018 Academic Article GET IT
Times cited: 73
Eosinophilic esophagitis as possible complication of aspirin treatment in patient with aspirin-exacerbated respiratory disease. 2016 GET IT
Times cited: 3
The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium. The American journal of gastroenterology. 2016 Academic Article GET IT
Times cited: 232
Xenobiotic Receptor-Mediated Regulation of Intestinal Barrier Function and Innate Immunity. Nuclear receptor research. 2016 Academic Article GET IT
Microbial control of intestinal innate immunity. Oncotarget. 2015 Editorial Article GET IT
Times cited: 9
Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease and Previous Cancer Exposed to Immunosuppressive and Anti-Tumor Necrosis Factor Agents. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association. 2015 Academic Article GET IT
Times cited: 77
p53 Promotes cell survival due to the reversibility of its cell-cycle checkpoints. Molecular cancer research : MCR. 2014 Academic Article GET IT
Times cited: 61
Long-lived intestinal tuft cells serve as colon cancer-initiating cells. The Journal of clinical investigation. 2014 Academic Article GET IT
Times cited: 265
Effect of comorbid conditions on adherence to colorectal cancer screening. Journal of cancer education : the official journal of the American Association for Cancer Education. 2012 Academic Article GET IT
Times cited: 18
p53 basic C terminus regulates p53 functions through DNA binding modulation of subset of target genes. The Journal of biological chemistry. 2012 Academic Article GET IT
Times cited: 30
Posttranslational processing and differential glycosylation of Tractin, an Ig-superfamily member involved in regulation of axonal outgrowth. Biochimica et biophysica acta. 2000 Academic Article GET IT
Times cited: 9
Glutathione synthesis is essential for mouse development but not for cell growth in culture. Proceedings of the National Academy of Sciences of the United States of America. 2000 Academic Article GET IT
Times cited: 238

more ...

less ...

Research

Sort by

Co-investigator Network

Funding awarded

Advanced Fellowship in Inflammatory Bowel Disease, Jill Roberts Center For IBD awarded by Takeda Pharmaceutical Company Limited Principal Investigator 2022 - 2023
Weill Cornell Medicine Advanced IBD Fellowship 2021-22 awarded by Janssen Scientific Principal Investigator 2021 - 2023

Molecular and clinical characterization of IBD patients naive or refractory to standard of care over time awarded by Boehringer Ingelheim Pharmaceuticals, Inc. (Germany) Co-Investigator 2023 - 2024

CHASE-EIM: Cohort for Healing Arthritis, Skin, and Eye Extra-Intestinal Manifestations awarded by Crohn''s & Colitis Foundation of America, Inc. Principal Investigator Subaward 2022 - 2024

more ...

less ...

Background

education and training

M.D., Mount Sinai School of Medicine 2007
Ph.D., Mount Sinai School of Medicine 2006
B.S., State University of New York at Buffalo 1999

Contact

full name

Dana Jeremy Lukin

primary email

djl9010@med.cornell.edu

webpage

Clinical Profile

VIVO Weill Cornell Medical College

Dana Jeremy Lukin Associate Professor of Clinical Medicine

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email

webpage

Phone

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email

webpage